Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs

被引:18
|
作者
DeAngelo, Jessica [1 ]
Jarrell, Daniel [1 ]
Cosgrove, Richard [1 ]
Camamo, James [1 ]
Edwards, Christopher [1 ]
Patanwala, Asad E. [2 ]
机构
[1] Banner Univ Med Ctr Tucson, Dept Pharm Serv, Tucson, AZ USA
[2] Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, Tucson, AZ USA
关键词
anticoagulants; warfarin; blood coagulation factors; hemorrhage; INTERNATIONAL NORMALIZED RATIO; CONSENSUS GUIDELINES; THROMBOSIS;
D O I
10.1097/MJT.0000000000000643
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Prothrombin complex concentrates (PCCs) are drug products containing varying amounts of vitamin K-dependent coagulation factors II, VII, IX, and X. The evidence comparing 3-factor PCC (3-PCC) versus 4-factor PCC (4-PCC) for warfarin reversal is conflicting. It has been hypothesized that 3-PCC may be less effective than 4-PCC because of relatively lower factor VII content. Study Question: The primary objective of this study was to compare international normalized ratio (INR) reversal between 3-PCC and 4-factor PCC (4-PCC) in warfarin-treated patients. The secondary objectives include comparing blood product use, total reversal costs, and cost-effectiveness between the groups. Study Design: This was a retrospective cohort study conducted in 2 affiliated, academic institutions in the United States. Consecutive adult patients who received 3-PCC or 4-PCC for warfarin reversal were included. Measures and Outcomes: The primary outcome was adequate INR reversal defined as a final INR <= 1.5. Secondary outcomes were the utilization of plasma, red blood cells and platelets, reversal costs, and the cost-effectiveness ratio. Results: There were 89 patients who were included in the overall cohort (3-PCC = 57, 4-PCC = 32). Adequate INR reversal occurred less commonly with 3-PCC (45.6%) compared with 4-PCC (87.5%) (P < 0.001). There was no significant difference in the proportion of patients who received plasma (32% vs. 28%, P = 0.813), red blood cells (37% vs. 47%, P = 0.377), or platelets (16% vs. 28%, P = 0.180) between the 3-PCC and 4-PCC groups, respectively. The median reversal cost of 3-PCC ($3663) was lower than 4-PCC ($5105) (P = 0.001). The cost-effective ratio favored 4-PCC ($5105/87.5% = $5834) compared with 3-PCC ($3663/45.6% = $8033). Conclusions: Four-PCC was more effective than 3-PCC with regard to INR reversal in patients taking warfarin, but blood product use was similar. Although 4-PCC is associated with increased reversal costs, it may be cost-effective in terms of INR reversal.
引用
收藏
页码:E326 / E332
页数:7
相关论文
共 50 条
  • [1] Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa
    Barton, Cassie A.
    Hom, Marissa
    Johnson, Nathan B.
    Case, Jon
    Ran, Ran
    Schreiber, Martin
    AMERICAN JOURNAL OF SURGERY, 2018, 215 (05): : 775 - 779
  • [2] Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa"
    Van Dusen, Rachel
    AMERICAN JOURNAL OF SURGERY, 2018, 215 (05): : 780 - 781
  • [3] Comparison of blood product use and costs with use of 3-factor versus 4-factor prothrombin complex concentrate for off-label indications
    DeAngelo, Jessica
    Jarrell, Daniel H.
    Cosgrove, Richard
    Camamo, James
    Edwards, Christopher J.
    Patanwala, Asad E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (15) : 1103 - 1109
  • [4] Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: Does it matter?
    Voils, Stacy A.
    Baird, Brian
    THROMBOSIS RESEARCH, 2012, 130 (06) : 833 - 840
  • [5] Comparative Thromboembolic Risk of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
    Wagner, S.
    Kaide, C.
    Li, J.
    Reichert, E.
    ANNALS OF EMERGENCY MEDICINE, 2019, 74 (04) : S120 - S120
  • [6] 3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors
    Hays, William Blake
    Billups, Kelsey
    Nicholson, Jessica
    Bailey, Abby M.
    Gregory, Haili
    Weeda, Erin R.
    Weant, Kyle A.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2025, 58 (02) : 276 - 283
  • [7] Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
    David J. Margraf
    Sarah J. Brown
    Heather L. Blue
    Tamara L. Bezdicek
    Julian Wolfson
    Scott A. Chapman
    BMC Emergency Medicine, 22
  • [8] Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
    Margraf, David J.
    Brown, Sarah J.
    Blue, Heather L.
    Bezdicek, Tamara L.
    Wolfson, Julian
    Chapman, Scott A.
    BMC EMERGENCY MEDICINE, 2022, 22 (01)
  • [9] EVALUATION OF WARFARIN REVERSAL WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE COMPARED TO 3-FACTOR PROTHROMBIN COMPLEX CONCENTRATE AT A TERTIARY ACADEMIC MEDICAL CENTER
    Al-Majzoub, Omar
    Rybak, Eva
    Reardon, David P.
    Krause, Patricia
    Connors, Jean M.
    JOURNAL OF EMERGENCY MEDICINE, 2016, 50 (01): : 7 - 13
  • [10] Comparison of 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin in emergency situations.
    Zane, Laura
    Reichert, Marc
    PHARMACOTHERAPY, 2015, 35 (05): : E68 - E69